ANVS Stock Price, Annovis Bio Inc Quote, Chart

Market Summary

USD5.18-0.27

Delayed

-4.95%

ANVS Stock Price

View Fullscreen

ANVS RSI Chart

ANVS Valuation

Market Cap

57.0M

Price/Earnings (Trailing)

-1.01

Price/Sales (Trailing)

1.6K

EV/EBITDA

-0.91

Price/Free Cashflow

-1.43

ANVS Price/Sales (Trailing)

ANVS Profitability

EBT Margin

-152920.26%

Return on Equity

725.14%

Return on Assets

-550.58%

Free Cashflow Yield

-70.07%

ANVS Fundamentals

ANVS Revenue

Revenue (TTM)

36.8K

ANVS Earnings

Earnings (TTM)

-56.2M

Earnings Growth (Yr)

-187.51%

Earnings Growth (Qtr)

-50.94%

Breaking Down ANVS Revenue

Last 7 days

-71.2%

Last 30 days

-54.1%

Last 90 days

-48.5%

Trailing 12 Months

-63.2%

How does ANVS drawdown profile look like?

ANVS Financial Health

Current Ratio

2.39

ANVS Investor Care

Shares Dilution (1Y)

34.01%

Diluted EPS (TTM)

-6.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	877.3K	597.1K	316.9K	36.8K
2020	840.7K	946.3K	1.1M	1.2M
2019	0	0	0	735.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Annovis Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 20, 2023	mccarthy reid	acquired	-	-	-	-
Nov 20, 2023	hoffman michael b	acquired	1,000,000	6.07	164,745	-
Nov 20, 2023	maccecchini maria-luisa	acquired	249,999	6.07	41,186	president and ceo
Nov 20, 2023	bruck claudine	acquired	6,070	6.07	1,000	-
Nov 20, 2023	white mark k.	acquired	12,140	6.07	2,000	-
Nov 20, 2023	hagopian henry iii	acquired	5,001	6.07	824	chief financial officer
Nov 20, 2023	mccarthy reid	acquired	5,001	6.07	824	-
Nov 20, 2023	hoffman michael b	acquired	999,668	6.1	163,880	-
Nov 20, 2023	bruck claudine	acquired	-	-	-	-
Nov 20, 2023	maccecchini maria-luisa	acquired	249,917	6.1	40,970	president and ceo

Which funds bought or sold ANVS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Sterling Investment Advisors, Ltd.	unchanged	-	-233,743	409,051	0.12%
Apr 26, 2024	YHB Investment Advisors, Inc.	new	-	1,012	1,012	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-7.95	-160,376	226,805	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	-1,360	2,380	-%
Mar 11, 2024	VANGUARD GROUP INC	added	30.49	3,855,070	6,308,520	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	223,821	223,821	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	217,356	441,320	0.01%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	reduced	-4.88	2,488,990	5,335,990	0.01%

Are Funds Buying or Selling ANVS?

Are funds buying ANVS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANVS

No. of Funds

Unveiling Annovis Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 28, 2023	hirschman orin	4.24%	435,000	SC 13G/A
Nov 08, 2023	hirschman orin	5.4%	548,941	SC 13G
Jan 28, 2021	hirschman orin	4.26%	293,358	SC 13G/A
Jul 21, 2020	hirschman orin	7.27%	463,797	SC 13G
Jul 10, 2020	hirschman orin	4.23%	288,290	SC 13G/A
Apr 20, 2020	maccecchini maria-luisa	19.4%	1,414,489	SC 13D
Jan 30, 2020	hirschman orin	7.36%	480,000	SC 13G

Recent SEC filings of Annovis Bio Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 01, 2024	424B5	Prospectus Filed
May 01, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 26, 2024	8-K	Current Report
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to Annovis Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Annovis Bio Inc News

Latest updates

Annovis Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-	-	-	7,414	106,131	204,847	586,903	208,261	157,438	-
Operating Expenses	107.4%	5,920,091	2,853,770	2,534,150	3,229,210	1,909,673	1,603,757	2,543,629	583,162	870,962
S&GA Expenses	106.1%	3,035,946	1,472,969	709,648	839,627	497,470	884,859	1,687,151	516,716	108,780
R&D Expenses	108.9%	2,884,145	1,380,801	1,824,502	2,389,583	1,412,203	718,898	856,478	66,446	762,182
EBITDA Margin	-1115.5%	-394	-32.43	-14.13	-9.37	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-107.7%	-5,914,641	-2,848,216	-2,524,602	-3,199,673	-1,704,613	-1,006,354	-2,309,490	-441,590	-201,256
EBT Margin	-1115.5%	-394	-32.43	-14.13	-9.37	-	-	-	-	-
Net Income	-107.7%	-5,914,641	-2,848,216	-2,524,602	-3,199,673	-1,704,613	-1,006,354	-2,309,490	-441,590	-201,256
Net Income Margin	-1115.5%	-394	-32.43	-14.13	-9.37	-	-	-	-	-
Free Cashflow	-1.5%	-1,769,320	-1,743,408	-3,144,563	-2,474,868	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	-0.1%	10.00	10.00	23.00	26.00	36.00	37.00	40.00	44.00	46.00	48.00	49.00	6.00	8.00	9.00	10.00	11.00	1.00
Current Assets	-0.1%	10.00	10.00	23.00	26.00	36.00	37.00	40.00	44.00	46.00	48.00	49.00	6.00	8.00	9.00	10.00	11.00	1.00
Cash Equivalents	-9.4%	6.00	6.00	16.00	17.00	28.00	32.00	36.00	43.00	46.00	47.00	49.00	6.00	8.00	9.00	10.00	11.00	0.00
Liabilities	403.8%	18.00	4.00	2.00	5.00	8.00	3.00	1.00	1.00	2.00	1.00	1.00	2.00	1.00	0.00	1.00	1.00	3.00
Current Liabilities	20.0%	4.00	4.00	2.00	5.00	8.00	3.00	1.00	1.00	2.00	1.00	1.00	2.00	1.00	0.00	1.00	1.00	2.00
Shareholder's Equity	-216.4%	-7.75	7.00	21.00	20.00	28.00	35.00	39.00	43.00	44.00	47.00	49.00	4.00	8.00	9.00	9.00	11.00	-
Retained Earnings	-25.3%	-110	-88.05	-73.33	-63.79	-54.05	-46.33	-39.90	-33.96	-28.73	-22.81	-19.96	-17.44	-14.24	-12.53	-11.53	-9.22	-8.78
Additional Paid-In Capital	8.2%	103	95.00	94.00	84.00	82.00	81.00	79.00	77.00	73.00	69.00	69.00	22.00	22.00	22.00	21.00	20.00	0.00
Shares Outstanding	16.7%	11.00	9.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	-	-	-	-	-
Float	-	-	-	92.00	-	-	-	63.00	-	-	-	482	-	-	-	19.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	0.1%	-9,364	-9,369	-9,606	-11,626	-3,609	-3,987	-6,694	-3,021	-1,769	-1,743	-3,144	-2,474	-765	-922	-1,311	-970	-52.53	-44.68	-150	-228
Share Based Compensation	39.6%	882	632	1,571	1,542	1,458	2,356	1,904	3,435	3,880	786	8.00	24.00	125	629	1,111	-	-376*	-	-	9.00
Cashflow From Financing	-	8,765	-	8,572	7.00	-	-	-	5.00	-	-25.46	46,766	3.00	-	-	-45.39	12,089	-1.86	-3.62	-81.43	530

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANVS Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 38,790,603	$ 16,515,543
General and administrative	6,244,408	8,995,736
Total operating expenses	45,035,011	25,511,279
Operating loss	(45,035,011)	(25,511,279)
Other income (expense):
Interest income	667,898	182,712
Change in fair value of warrants	(11,837,200)
Total other (expense) income	(11,169,302)	182,712
Net loss before income taxes	(56,204,313)	(25,328,567)
Income tax expense (benefit)
Net loss	$ (56,204,313)	$ (25,328,567)
Basic loss per common share	$ (6.23)	$ (3.10)
Diluted loss per common share	$ (6.23)	$ (3.10)
Weighted average number of common shares outstanding, basic	9,023,138	8,162,326
Weighted average number of common shares outstanding, diluted	9,023,138	8,162,326

ANVS Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,754,720	$ 28,377,693
Prepaid expenses and other current assets	4,453,544	7,644,376
Total current assets	10,208,264	36,022,069
Total assets	10,208,264	36,022,069
Current liabilities:
Accounts payable	1,292,837	3,961,254
Accrued expenses	2,986,273	3,737,285
Total current liabilities	4,279,110	7,698,539
Warrant Liability	13,680,000
Total liabilities	17,959,110	7,698,539
Commitments and contingencies (Note 6)
Stockholders' (deficit) equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 70,000,000 shares authorized and 10,519,933 and 8,163,923 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	1,052	816
Additional paid-in capital	102,507,189	82,377,488
Accumulated deficit	(110,259,087)	(54,054,774)
Total stockholders' (deficit) equity	(7,750,846)	28,323,530
Total liabilities and stockholders' (deficit) equity	$ 10,208,264	$ 36,022,069

About Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

CEO	Dr. Maria L. Maccecchini Ph.D.
WEBSITE	annovisbio.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Annovis Bio Inc Frequently Asked Questions

What is the ticker symbol for Annovis Bio Inc? What does ANVS stand for in stocks?

ANVS is the stock ticker symbol of Annovis Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Annovis Bio Inc (ANVS)?

As of Fri May 03 2024, market cap of Annovis Bio Inc is 57.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANVS stock?

You can check ANVS's fair value in chart for subscribers.

What is the fair value of ANVS stock?

You can check ANVS's fair value in chart for subscribers. The fair value of Annovis Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Annovis Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Annovis Bio Inc a good stock to buy?

The fair value guage provides a quick view whether ANVS is over valued or under valued. Whether Annovis Bio Inc is cheap or expensive depends on the assumptions which impact Annovis Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANVS.

What is Annovis Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, ANVS's PE ratio (Price to Earnings) is -1.01 and Price to Sales (PS) ratio is 3.41 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANVS PE ratio will change depending on the future growth rate expectations of investors.